Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Conant Optical Co., Ltd. (2276.HK)
HKD29.16
-1.32 (-4.33%)
CN HKSE Healthcare Medical - Instruments & Supplies
Address
Building 36, Hongxiang North Rd
Shanghai, CN
Shanghai, CN
CEO
Zhengxiang Fei
Website
conantoptical.com.cn
IPO
2021-12-16
ISIN CNE100004Z14
Description
Shanghai Conant Optical Co., Ltd. specializes in the global production and sale of resin eyeglass lenses. The company's extensive reach covers continents such as Asia, Europe, North and South America, Africa, and Oceania, in addition to its home market of China. It supplies a diverse range of optical solutions, including both standardized products and custom-tailored lenses. Its primary clientele consists of brand owners within the spectacle lens industry and various ophthalmic optics enterprises. The firm was established in 2011 and operates from its headquarters in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD29.16
-1.32 (-4.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.29
Float Shares
389.77M
Free Float %
79.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.08% | -6.63% | -10.35% | -31.40% | -13.22% | -21.74% | +42.77% | +672.58% | +828.79% | +828.79% | +828.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
29.16
DCF (Unlevered)
44.07
+51.1%
DCF (Levered)
56.78
+94.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
17.87
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+6.1% Q4'25: +18.7% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+16.5% ★ Q4'25: +52.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+19.6% Q4'25: +15.6% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+27.6% ★ Q4'25: +28.2% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+33.6% ★ Q4'25: +70.3% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+11.8% Q4'25: +9.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.44× ★ Q4'25: 0.21× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 7 EPS Ana. |
Dec 2027 9 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.56B
est: 1.65B (-5.1%)
|
1.76B
est: 1.77B (-0.7%)
|
2.06B
est: 2.05B (+0.3%)
|
2.19B
est: 2.39B (-8.3%)
|
2.66B
2.52B – 2.79B
+11.5% YoY
|
3.26B
2.90B – 3.99B
+22.6% YoY
|
3.90B
3.57B – 4.47B
+19.6% YoY
|
| EBITDA |
354.97M
est: 401.69M (-11.6%)
|
465.77M
est: 737.37M (-36.8%)
|
582.03M
est: 854.84M (-31.9%)
|
682.24M
est: 992.52M (-31.3%)
|
1.11B
1.05B – 1.16B
+11.5% YoY
|
1.36B
1.21B – 1.66B
+22.6% YoY
|
1.62B
1.49B – 1.86B
+19.6% YoY
|
| EBIT |
307.28M
est: 343.56M (-10.6%)
|
406.66M
est: 667.31M (-39.1%)
|
507.59M
est: 773.62M (-34.4%)
|
602.27M
est: 898.22M (-32.9%)
|
1.00B
950.38M – 1.05B
+11.5% YoY
|
1.23B
1.09B – 1.50B
+22.6% YoY
|
1.47B
1.35B – 1.68B
+19.6% YoY
|
| Net Income |
248.57M
est: 289.04M (-14.0%)
|
327.02M
est: 350.85M (-6.8%)
|
428.28M
est: 449.18M (-4.7%)
|
557.72M
est: 566.19M (-1.5%)
|
698.57M
644.65M – 752.49M
+23.4% YoY
|
777.79M
764.39M – 1.21B
+11.3% YoY
|
1.12B
990.13M – 1.25B
+43.8% YoY
|
| SGA |
224.71M
est: 232.95M (-3.5%)
|
278.17M
est: 255.96M (+8.7%)
|
323.78M
est: 296.73M (+9.1%)
|
217.34M
est: 344.52M (-36.9%)
|
384.14M
364.53M – 402.51M
+11.5% YoY
|
471.09M
418.65M – 576.38M
+22.6% YoY
|
563.47M
515.90M – 645.26M
+19.6% YoY
|
| EPS |
0.58
est: 0.68 (-14.4%)
|
0.77
est: 0.83 (-7.2%)
|
1.02
est: 0.92 (+10.4%)
|
1.20
est: 1.20 (-0.1%)
|
1.47
1.38 – 1.62
+22.0% YoY
|
1.92
1.64 – 2.61
+30.9% YoY
|
2.42
2.13 – 2.68
+26.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
778.95M
OE per share TTM
1.77
Owner's Yield
3.98%
Maintenance CapEx ratio
52.84%
Maint CapEx / Avg PPE
30.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 59 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | abrdn International Small Cap Active ETF ASCI | 1.00% | 790.4K | 1.05% |
| 2 | iShares MSCI China Small-Cap ETF ECNS | 0.55% | 355.6K | 0.59% |
| 3 | VictoryShares Emerging Markets Value Momentum ETF UEVM | 0.30% | 737.1K | 0.53% |
| 4 | abrdn Emerging Markets Dividend Active ETF AGEM | 0.16% | 580.5K | 1.18% |
| 5 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.11% | 2.01M | 0.58% |
| 6 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.10% | 45.3K | 0.54% |
| 7 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.07% | 53.1K | 0.74% |
| 8 | iShares Ageing Population UCITS ETF AGED.L | 0.07% | 602.6K | 0.40% |
| 9 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.05% | 319.7K | 0.55% |
| 10 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.05% | 183.9K | 0.72% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
221.2K
Shares Outstanding
489.57M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuhong Zheng | Deputy GM & Executive Director | 3M | male |
| Zhengxiang Fei | Executive Chairman of the Board & GM | 3M | male |
| Junhua Chen | Executive Director | 2M | male |
| Chuanbao Wang | Executive Director | 2M | male |
| Guoping Xia | Executive Director | 2M | male |
| Xue Cao | Joint Company Secretary & Executive Director | 2M | female |
| Pui Hang Chan | Joint Company Secretary | — | male |
| Huyin Xu | Financial Controller | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2276.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
